华兰疫苗：关于重组带状疱疹疫苗（CHO细胞）获得药物临床试验批准通知书的公告

Group 1 - The core point of the article is that Hualan Vaccine has received approval from the National Medical Products Administration for the clinical trial of its recombinant varicella-zoster virus vaccine (CHO cell) [2] Group 2 - The approval signifies a significant step forward for the company in its vaccine development efforts [2] - This development may enhance the company's position in the vaccine market, particularly in the area of shingles prevention [2] - The announcement reflects ongoing regulatory support for vaccine innovation in the industry [2]